Entia Biosciences Inc
OTC:ERGO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Entia Biosciences Inc
Free Cash Flow
Entia Biosciences Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Entia Biosciences Inc
OTC:ERGO
|
Free Cash Flow
-$715.1k
|
CAGR 3-Years
4%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Estee Lauder Companies Inc
NYSE:EL
|
Free Cash Flow
$1.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
|
Bellring Brands Inc
NYSE:BRBR
|
Free Cash Flow
$246.9m
|
CAGR 3-Years
56%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Coty Inc
NYSE:COTY
|
Free Cash Flow
$277.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inter Parfums Inc
NASDAQ:IPAR
|
Free Cash Flow
$166.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
elf Beauty Inc
NYSE:ELF
|
Free Cash Flow
$214.5m
|
CAGR 3-Years
40%
|
CAGR 5-Years
151%
|
CAGR 10-Years
31%
|
|
Entia Biosciences Inc
Glance View
Entia Biosciences, Inc. operates as a biotechnology company. The company is headquartered in Sherwood, Oregon. The company went IPO on 2007-11-01. The firm also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. The firm's ErgoD2 formulations utilize organically cultivated specialty mushrooms available from various domestic and international suppliers. These mushroom-based products are generally regarded as safe (GRAS). The firm's market and scientific research has identified mushroom species and suppliers to provide the nutritional profiles for its ErgoD2 formulations.
See Also
What is Entia Biosciences Inc's Free Cash Flow?
Free Cash Flow
-715.1k
USD
Based on the financial report for Dec 31, 2016, Entia Biosciences Inc's Free Cash Flow amounts to -715.1k USD.
What is Entia Biosciences Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-27%
Over the last year, the Free Cash Flow growth was -31%. The average annual Free Cash Flow growth rates for Entia Biosciences Inc have been 4% over the past three years , -27% over the past five years .
